ARTV
Artiva Biotherapeutics, Inc. Common Stock
NASDAQ: ARTV · HEALTHCARE · BIOTECHNOLOGY
$10.24
+17.43% today
Updated 2026-04-30
Market cap
$253.10M
P/E ratio
—
P/S ratio
8.11x
EPS (TTM)
$-3.43
Dividend yield
—
52W range
$1 – $15
Volume
0.3M
Artiva Biotherapeutics, Inc. Common Stock (ARTV) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
0 of 8
Last 8 quarters
Avg EPS surprise
-15.5%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-27.3%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+12.6%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+28.5%
2026-03-30
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-30 | $-0.84 | -5.0% | $5.01 | $6.44 | +28.5% |
| 2025-11-18 | $-0.88 | -10.0% | $3.51 | $3.39 | -3.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.80 | $-0.84 | -5.0% | — | — |
| 2025-09-30 | $-0.80 | $-0.88 | -10.0% | — | — |
| 2025-06-30 | $-0.77 | $-0.87 | -13.0% | — | — |
| 2025-03-31 | $-0.62 | $-0.83 | -33.9% | — | — |
| 2024-12-31 | $-0.58 | $-0.66 | -13.8% | — | — |
| 2024-09-30 | $-0.63 | $-0.87 | -38.1% | — | — |
| 2024-06-30 | $-4.40 | $-22.00 | -400.0% | — | — |
| 2024-03-31 | $0.00 | $-1.49 | — | $251000.00 | — |
Frequently asked questions
Has Artiva Biotherapeutics, Inc. Common Stock beaten earnings estimates?
Artiva Biotherapeutics, Inc. Common Stock has beaten Wall Street EPS estimates in 0 of its last 8 quarterly reports, with an average EPS surprise of -15.5% over the last 4 quarters.
How does ARTV stock react to earnings?
ARTV stock has moved an average of +12.6% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.